The article reviews the advancements and potential of CAR T-cell therapy in treating multiple myeloma (MM). CAR T-cell therapy, a cutting-edge treatment method, has emerged as a game-changer in MM care, complementing existing treatments like autologous stem cell transplants and immunomodulatory medications. The recent FDA approval of the second CAR T-cell therapy for MM has sparked significant promise. Preclinical and clinical trials are exploring the capabilities of CAR T-cells in targeting specific antigens on myeloma cells, offering hope for relapsed/refractory MM patients. The article delves into the history and functions of CAR T-cells, their structure, and the challenges they face. It also discusses the development and efficacy of various CAR T-cell therapies, including BB2121, LCAR-B38M, P-BCMA-101, MCARH171, BRD015, Descartes-08, CT103A, CD19-CAR T-cell, CD19/BCMA CAR T-cell, Kappa light chain-CAR T-cell, NY-ESO-1-CAR T-cell, CD56-CAR T-cell, CD70-CAR T-cell, CD138-CAR T-cell, SLAMF7-CAR T-cell, and ANTITACI CAR T-cell. The article highlights the potential of these therapies in improving treatment outcomes and minimizing side effects, while also addressing the limitations and safety concerns associated with CAR T-cell therapy.The article reviews the advancements and potential of CAR T-cell therapy in treating multiple myeloma (MM). CAR T-cell therapy, a cutting-edge treatment method, has emerged as a game-changer in MM care, complementing existing treatments like autologous stem cell transplants and immunomodulatory medications. The recent FDA approval of the second CAR T-cell therapy for MM has sparked significant promise. Preclinical and clinical trials are exploring the capabilities of CAR T-cells in targeting specific antigens on myeloma cells, offering hope for relapsed/refractory MM patients. The article delves into the history and functions of CAR T-cells, their structure, and the challenges they face. It also discusses the development and efficacy of various CAR T-cell therapies, including BB2121, LCAR-B38M, P-BCMA-101, MCARH171, BRD015, Descartes-08, CT103A, CD19-CAR T-cell, CD19/BCMA CAR T-cell, Kappa light chain-CAR T-cell, NY-ESO-1-CAR T-cell, CD56-CAR T-cell, CD70-CAR T-cell, CD138-CAR T-cell, SLAMF7-CAR T-cell, and ANTITACI CAR T-cell. The article highlights the potential of these therapies in improving treatment outcomes and minimizing side effects, while also addressing the limitations and safety concerns associated with CAR T-cell therapy.